JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Metabolomics-based combination of GH and NVB in the treatment of NSCLC lung cancer recurrence

  • 0Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, 210009, China.
Journal of Cancer +

|

January 2, 2025

|

January 2, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

This study shows that combining Ginsenoside H (GH) and vinorelbine (NVB) effectively treats recurrent Non-Small Cell Lung Cancer (NSCLC), achieving a 74.81% inhibition rate. Metabolomic analysis identified key biomarkers for lung cancer detection and treatment monitoring.

Area Of Science

  • Oncology
  • Pharmacology
  • Metabolomics

Background

  • Lung cancer, particularly Non-Small Cell Lung Cancer (NSCLC), presents significant global health challenges due to early asymptomatic stages and high recurrence rates.
  • Conventional treatments for lung cancer often face limitations in efficacy, especially for recurrent cases, necessitating novel therapeutic strategies.

Purpose Of The Study

  • To investigate the efficacy of a combination therapy using Ginsenoside H dripping pills (GH) and vinorelbine (NVB) for treating recurrent NSCLC.
  • To identify potential metabolic biomarkers associated with lung cancer recurrence and treatment response using metabolomics.

Main Methods

  • Construction of a Non-Small Cell Lung Cancer (NSCLC) recurrence model.
  • Treatment of the recurrence model with GH, NVB, and a combination of GH and NVB.
  • GC-TOF/MS-based metabolomics to analyze metabolite profiles in different treatment groups and identify differentially abundant metabolites.
  • Analysis of metabolic pathways affected by the combined treatment.

Main Results

  • The combined GH and NVB treatment demonstrated a significantly higher inhibition rate (74.81%) compared to individual treatments.
  • Metabolomic analysis revealed 12 differentially abundant metabolites, including glucose 6-phosphate, palmitoleic acid, linoleic acid, guanine, and allantoic acid, across treatment groups.
  • These metabolite changes involve glucose and lipid metabolism, amino acid metabolism, and purine metabolism, indicating a broad impact on cellular processes.

Conclusions

  • The combination of GH and NVB offers a potent therapeutic strategy for recurrent NSCLC, surpassing the efficacy of monotherapies.
  • The identified metabolites serve as potential biomarkers for detecting lung cancer and monitoring treatment effectiveness.
  • The combined therapy effectively regulates purine metabolism, folate synthesis, and thiamine metabolism, leading to a reduction in alkaline phosphatase (AP) levels.

Keywords: